Drugs / MUC-2-KLH vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004929 | Sep 1999 → Jun 2008 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC-2-KLH vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004929 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00004929 ↗ |
| Modality | Vaccine | “Vaccine Therapy” NCT00004929 ↗ |
| Target | MUC2 | “response against glycosylated MUC-2” NCT00004929 ↗ |